Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening
Mirxes Holding Company Ltd, a Singapore‑headquartered RNA technology company, announced a strategic partnership with N...
Santen’s UPNEEQ Wins Japan Approval for Acquired Ptosis
Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved...
Biocytogen Licenses ADC Programs to Acepodia in Option Deal
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement...
Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO
Simcere Pharmaceutical Group Limited (HKG: 2096) announced plans to spin off its subsidiary Simcere Zaiming...
Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform
Nona Biosciences, a wholly‑owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi‑target antibody...
Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that the National Medical Products...
Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution
Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical...
FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development
The FDA’s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle‑based approach to...
Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia
Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long‑acting triple‑target agonist developed by...
Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced that the New Drug Application (NDA)...
Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity
Novartis AG (NYSE: NVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in...
Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery
Pierre Fabre Laboratories announced a comprehensive drug discovery collaboration with French AI specialist Iktos to...
NHSA Launches Personal Healthcare Insurance Cloud Pilot Program
China’s National Healthcare Security Administration (NHSA) issued a notice inviting applications for pilot projects to...
China Expands Medical Insurance Personal Account Pooling Nationwide
China’s National Healthcare Security Administration (NHSA) and Ministry of Finance (MoF) jointly issued the “Notice...
Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced it has granted AirNexis Therapeutics exclusive worldwide...
Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset
Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset...
Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen’s...
Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
Johnson & Johnson (J&J, NYSE: JNJ) announced a voluntary agreement with the Trump Administration to...
Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out‑licensing agreement with Vitamedic Health Nutraceuticals (Brazil),...
Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) is reportedly in advanced negotiations to acquire Revolution Medicines...